A.W.J. Martens publications

foto

Publications A.W.J. Martens

Position
PhD Candidate
Main activities
Research
Specialisation
T cell dysfunction in chronic lymphocytic leukemia
Focus of research

Characterizing T cell dysfunction in CLL and testing new T cell based therapies.

2020

  • Martens Anne W. J., Janssen Susanne R., Derks Ingrid A. M., Adams Iii Homer C., Izhak Liat, van Kampen Roel, Tonino Sanne H., Eldering Eric, van der Windt Gerritje J. W., Kater Arnon P. CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells Journal for immunotherapy of cancer 2020;8 (1) [PubMed]
  • Hofland Tom, Martens Anne W. J., van Bruggen Jaco A. C., de Boer Renate, Schetters Sjoerd, Remmerswaal Ester B. M., Bemelman Frederike J., Levin Mark-David, Bins Adriaan D., Eldering Eric, Kater Arnon P., Tonino Sanne H. Human CXCR5+PD-1+ CD8 T cells in healthy individuals and patients with hematologic malignancies European journal of immunology 2020 [PubMed]
  • Salio Mariolina, Awad Wael, Veerapen Natacha, Gonzalez-Lopez Claudia, Kulicke Corinna, Waithe Dominic, Martens Anne W. J., Lewinsohn David M., Hobrath Judith V., Cox Liam R., Rossjohn Jamie, Besra Gurdyal S., Cerundolo Vincenzo Ligand-dependent downregulation of MR1 cell surface expression Proceedings of the National Academy of Sciences of the United States of America 2020;117 (19):10465-10475 [PubMed]
  • van Bruggen Jaco A. C., Martens Anne W. J., Tonino Sanne H., Kater Arnon P. Overcoming the hurdles of autologous t‐cell‐based therapies in b‐cell non‐hodgkin lymphoma Cancers 2020;12 (12):1-31 [PubMed]

2019

  • van Bruggen Jaco A. C., Martens Anne W. J., Fraietta Joseph A., Hofland Tom, Tonino Sanne H., Eldering Eric, Levin Mark-David, Siska Peter J., Endstra Sanne, Rathmell Jeffrey C., June Carl H., Porter David L., Melenhorst J. Joseph, Kater Arnon P., van der Windt Gerritje J. W. Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T-cell efficacy Blood 2019;134 (1):44-58 [PubMed]